Management of hepatitis C in patients with chronic kidney disease

被引:0
作者
Roberto J Carvalho-Filho [1 ]
Ana Cristina CA Feldner [1 ]
Antonio Eduardo B Silva [1 ]
Maria Lucia G Ferraz [1 ]
机构
[1] Division of Gastroenterology,Hepatology Section,Federal University of Sao Paulo,Sao Paulo,SP 04023-900,Brazil
关键词
Hepatitis C virus; Chronic kidney disease; End-stage renal disease; Hemodialysis; Kidney transplantation; Diagnosis; Conservative management; Therapy;
D O I
暂无
中图分类号
R692 [肾疾病]; R512.63 [];
学科分类号
1002 ; 100210 ; 100401 ;
摘要
Hepatitis C virus(HCV) infection is highly prevalent among chronic kidney disease(CKD) subjects under hemodialysis and in kidney transplantation(KT) recipients, being an important cause of morbidity and mortality in these patients. The vast majority of HCV chronic infections in the hemodialysis setting are currently attributable to nosocomial transmission. Acute and chronic hepatitis C exhibits distinct clinical and laboratorial features, which can impact on managementand treatment decisions. In hemodialysis subjects, acute infections are usually asymptomatic and anicteric; since spontaneous viral clearance is very uncommon in this context, acute infections should be treated as soon as possible. In KT recipients, the occurrence of acute hepatitis C can have a more severe course, with a rapid progression of liver fibrosis. In these patients, it is recommended to use pegylated interferon(PEG-IFN) in combination with ribavirin, with doses adjusted according to estimated glomerular filtration rate. There is no evidence suggesting that chronic hepatitis C exhibits a more aggressive course in CKD subjects under conservative management. In these subjects, indication of treatment with PEG-IFN plus ribavirin relies on the CKD stage, rate of progression of renal dysfunction and the possibility of a preemptive transplant. HCV infection has been associated with both liver disease-related deaths and cardiovascular mortality in hemodialysis patients. Among those individuals, low HCV viral loads and the phenomenon of intermittent HCV viremia are often observed, and sequential HCV RNA monitoring is needed. Despite the poor tolerability and suboptimal efficacy of antiviral therapy in CKD patients, many patients can achieve sustained virological response, which improve patient and graft outcomes. Hepatitis C eradication before KT theoretically improves survival and reduces the occurrence of chronic graft nephropathy, de novo glomerulonephritis and post-transplant diabetes mellitus.
引用
收藏
页码:408 / 422
页数:15
相关论文
共 88 条
[21]  
Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality?[J] . F. Fabrizi,V. Dixit,P. Messa.Journal of Viral Hepatitis . 2012 (9)
[22]   Histological evolution of hepatitis C virus infection after renal transplantation [J].
de Oliveira Uehara, Silvia Naomi ;
Emori, Christini Takemi ;
Fucuta Pereira, Patricia da Silva ;
Perez, Renata M. ;
Medina Pestana, Jose Osmar ;
Lanzoni, Valeria Pereira ;
Souza e Silva, Ivonete Sandra ;
Benedito Silva, Antonio Eduardo ;
Cardoso Gomes Ferraz, Maria Lucia .
CLINICAL TRANSPLANTATION, 2012, 26 (06) :842-848
[23]   New Virologic Tools for Management of Chronic Hepatitis B and C [J].
Chevaliez, Stephane ;
Rodriguez, Christophe ;
Pawlotsky, Jean-Michel .
GASTROENTEROLOGY, 2012, 142 (06) :1303-+
[24]   Experience of Fibrosing Cholestatic Hepatitis With Hepatitis C Virus in Kidney Transplant Recipients [J].
Siddiqui, A. R. ;
Abbas, Z. ;
Luck, N. H. ;
Hassan, S. M. ;
Aziz, T. ;
Mubarak, M. ;
Naqvi, S. A. ;
Rizvi, S. A. H. .
TRANSPLANTATION PROCEEDINGS, 2012, 44 (03) :721-724
[25]  
1101 THE EFFECT OF RENAL IMPAIRMENT AND END STAGE RENAL DISEASE ON THE SINGLE-DOSE PHARMACOKINETICS OF PSI-7977[J] . M.T. Cornpropst,J.M. Denning,D. Clemons,T.C. Marbury,H. Alcorn,W.B. Smith,M. Sale,L. Fang,M.M. Berrey,W.T. Symonds.Journal of Hepatology . 2012
[26]  
Interferon therapy of acute hepatitis C in dialysis patients: meta‐analysis[J] . F. Fabrizi,V. Dixit,P. Messa,P. Martin.Journal of Viral Hepatitis . 2012 (11)
[27]   Transcription-mediated amplification (TMA) for the assessment of viremia in hemodialysis patients with hepatitis C [J].
Bastos, Dauana O. ;
Perez, Renata M. ;
Silva, Ivonete Souza ;
Lemos, Lara Barros ;
Simonetti, Jose Pascoal ;
Medina-Pestana, Jose Osmar ;
Silva, Antonio Eduardo B. ;
Ferraz, Maria Lucia .
JOURNAL OF MEDICAL VIROLOGY, 2012, 84 (04) :596-600
[28]  
The impact of hepatitis C virus donor and recipient status on long‐term kidney transplant outcomes: University of Wisconsin experience[J] . Neeraj Singh,Nikole Neidlinger,Arjang Djamali,Glen Leverson,Barbara Voss,Hans W. Sollinger,John D. Pirsch.Clinical Transplantation . 2012 (5)
[29]  
Dermatological side effects of hepatitis C and its treatment: Patient management in the era of direct-acting antivirals[J] . Patrice Cacoub,Marc Bourlière,Jann Lübbe,Nicolas Dupin,Peter Buggisch,Geoffrey Dusheiko,Christophe Hézode,Odile Picard,Ramon Pujol,Siegfried Segaert,Bing Thio,Jean-Claude Roujeau.Journal of Hepatology . 2011 (2)
[30]   Does the antiviral therapy of patients with chronic hepatitis exert nephrotoxic effects? [J].
Gluhovschi, Cristina ;
Gadalean, Florica ;
Kaycsa, Adriana ;
Curescu, Manuela ;
Sporea, Ioan ;
Gluhovschi, Gheorghe ;
Petrica, Ligia ;
Velciov, Silvia ;
Bozdog, Gheorghe ;
Bob, Flaviu ;
Vernic, Corina ;
Cioca, Daniel .
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2011, 33 (04) :744-750